Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

Have you evaluated the performance of Charles River Laboratories' (CRL) international operations during the quarter that concluded in September 2025? Considering the extensive worldwide presence of ...

CRL has consistently achieved ROE values above 12% since 2018. In addition, in the same period, its liabilities-to-assets ratio has exhibited a downward trend. The company has seen a considerable ...

Charles River Laboratories International Inc CRL reported Q1 sales of $1.03 billion, an increase of 12.6% Y/Y, beating the consensus of $986.35 million. The company reported adjusted EPS of $2.78, ...

Charles River Laboratories (CRL) reported $1.06 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 8.9%. EPS of $2.69 for the same period compares to $2.77 a ...

The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River ...

Detailed price information for Charles River Laboratories Intl (CRL-N) from The Globe and Mail including charting and trades.